Small clinical cohorts are a reality in translational oncology, making reliable model validation essential. Our ESMO AI 2026 poster examines how cross-validation design affects reported biomarker performance and what this means for evaluating predictions when clinical data are limited.
Published for ESMO AI 2026.
Authors:
Miha Štajdohar, Gregor Jerše
Genialis, Inc., Boston, MA, USA
